Internal Medicine, Rheumatology · Boston, MA
NPI
1306264577
Since 2014
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
55 Fruit St
Boston, MA, 02114
Phone (617) 726-7938
Groups this clinician bills Medicare through
Medicare paid, 2024
$85K
3,036 services
Medicare patients, 2024
393
Average age 74
Drug cost, 2024
$2.4M
1,166 prescriptions
Company payments, 2025
$2,649
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark A Matza was code J1010 (injection, methylprednisolone acetate, 1 mg), 1,920 times for 20 patients. In total Mark A Matza billed 3,036 services in 27 codes, and Medicare paid $85K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,920 | 20 | $0.10 | $198 |
| 99214 Office E&M - Established | Office | 198 | 135 | $102.65 | $20K |
| 99214 Office E&M - Established | Facility | 191 | 160 | $72.09 | $14K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 148 | 76 | $13.79 | $2,041 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 114 | 83 | $13.75 | $1,568 |
| 99215 Office E&M - Established | Office | 93 | 59 | $147.50 | $14K |
| 99215 Office E&M - Established | Facility | 74 | 64 | $115.81 | $8,570 |
| 76881 Ultrasound - Nonspecific | Office | 43 | 33 | $46.15 | $1,985 |
| 76882 Ultrasound - Nonspecific | Office | 37 | 24 | $56.16 | $2,078 |
| 99205 Office E&M - New | Office | 32 | 32 | $182.26 | $5,832 |
| 99232 Hospital E&M - Subsequent | Facility | 23 | 16 | $64.65 | $1,487 |
| 20611 Joint Injection | Office | 22 | 18 | $90.97 | $2,001 |
| 99443 Telephone Services | Facility | 20 | 15 | $69.20 | $1,384 |
| 99213 Office E&M - Established | Office | 20 | 16 | $71.24 | $1,425 |
| 99204 Office E&M - New | Office | 18 | 18 | $134.84 | $2,427 |
By year: 2022 $72K for 858 services; 2023 $76K for 984 services; 2024 $85K for 3,036 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark A Matza prescribed most often to Medicare patients was Prednisone, with 198 prescriptions and refills. In total Mark A Matza wrote 1,166 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 198 | 354 | 63 | $1,982 |
| Actemra Actpen Tocilizumab | 154 | 154 | 19 | $641K |
| Methotrexate Methotrexate Sodium | 105 | 218 | 29 | $2,180 |
| Allopurinol Generic | 105 | 250 | 25 | $1,175 |
| Hydroxychloroquine Sulfate Generic | 102 | 241 | 26 | $3,766 |
| Alendronate Sodium Generic | 53 | 149 | 20 | $560 |
| Actemra Tocilizumab | 51 | 51 | Under 11 | $155K |
| Humira(Cf) Pen Adalimumab | 45 | 46 | Under 11 | $492K |
| Enbrel Sureclick Etanercept | 39 | 39 | Under 11 | $272K |
| Cosentyx Sensoready Pen Secukinumab | 38 | 38 | Under 11 | $280K |
| Mycophenolate Mofetil Generic | 32 | 46 | Under 11 | $5,153 |
| Folic Acid Generic | 24 | 72 | Under 11 | $404 |
| Leflunomide Generic | 18 | 44 | Under 11 | $1,727 |
| Meloxicam Generic | 17 | 23 | Under 11 | $145 |
| Kevzara Sarilumab | 17 | 17 | Under 11 | $72K |
Brand drugs: 415 claims; generic drugs: 751 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark A Matza $2,649 ($2,649 in general payments such as food, travel and fees) from 2 companies. The largest payer was Janssen Biotech, Inc. with $2,445.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.